Seres Therapeutics amends asset sale agreement with Nestlé to terminate future milestone payments
Seres Therapeutics and Société des Produits Nestlé S.A. amended their August 2024 asset purchase agreement to terminate Nestlé's obligations for second and third sales milestone payments and related interest accruals. The modification reduces Seres' potential future contingent payments from the product asset sale.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day